Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. The company trades on NASDAQ exchange. The company headquarter is located in Ponte Vedra, FL. The company was established in the 2022.

TickerCVKD
Long NameCadrenal Therapeutics, Inc.
Short NameCadrenal Therapeutics